PURPOSE: Adrenal incidentalomas (AI) are discovered after work-up unrelated to adrenal gland diseases; up to 30% of AI show subclinical endogenous cortisol excess (SH), frequently associated to hypertension, obesity, metabolic disorders and increased incidence of cardiovascular events (CVEs). METHODS: We analysed 628 AI patients divided into two groups: 471 non-functional adrenal adenoma (NFA) and 157 SH. All patients underwent complete examinations, 24-h ambulatory blood pressure monitoring, biohumoral parameters and vascular damage markers, such as c-IMT and ankle brachial index. After long-term follow-up, we registered newly onset of CVEs such as myocardial infarction (MI), percutaneous stenting and surgical bypass (PTA/CABG), stroke, overall/cardiovascular mortality. Moreover, SH patients underwent to surgical (SSH) or pharmacological treatment (MSH). RESULTS: SH patients showed higher prevalence of metabolic syndrome, diabetes mellitus, and previous CVEs respect NFA at baseline. After follow-up MSH group showed higher recurrence of major CV events compared with NFA and SSH (RR 2.27 MSH vs NFA for MI; RR 2.30 MSH vs NFA for PTA/CABG; RR 2.41 MSH vs NFA for stroke). In SSH there was a significant reduction of the number of antihypertensive medications needed to reach target blood pressure levels (2.3 ± 1.0 to 1.5 ± 0.4 drugs). None differences were found in SH patients, distinguished in relation to cortisol plasma levels after dexamethasone suppression test (1.8-5 µg/dL, above 5 µg/dL). CONCLUSIONS: SH is linked to relevant cardiovascular and metabolic alterations, leading to worsen clinical outcomes. In eligible patients, adrenalectomy is valid and safe option to treat SH, reducing cardiometabolic abnormalities.
PURPOSE:Adrenal incidentalomas (AI) are discovered after work-up unrelated to adrenal gland diseases; up to 30% of AI show subclinical endogenous cortisol excess (SH), frequently associated to hypertension, obesity, metabolic disorders and increased incidence of cardiovascular events (CVEs). METHODS: We analysed 628 AIpatients divided into two groups: 471 non-functional adrenal adenoma (NFA) and 157 SH. All patients underwent complete examinations, 24-h ambulatory blood pressure monitoring, biohumoral parameters and vascular damage markers, such as c-IMT and ankle brachial index. After long-term follow-up, we registered newly onset of CVEs such as myocardial infarction (MI), percutaneous stenting and surgical bypass (PTA/CABG), stroke, overall/cardiovascular mortality. Moreover, SH patients underwent to surgical (SSH) or pharmacological treatment (MSH). RESULTS: SH patients showed higher prevalence of metabolic syndrome, diabetes mellitus, and previous CVEs respect NFA at baseline. After follow-up MSH group showed higher recurrence of major CV events compared with NFA and SSH (RR 2.27 MSH vs NFA for MI; RR 2.30 MSH vs NFA for PTA/CABG; RR 2.41 MSH vs NFA for stroke). In SSH there was a significant reduction of the number of antihypertensive medications needed to reach target blood pressure levels (2.3 ± 1.0 to 1.5 ± 0.4 drugs). None differences were found in SH patients, distinguished in relation to cortisol plasma levels after dexamethasone suppression test (1.8-5 µg/dL, above 5 µg/dL). CONCLUSIONS: SH is linked to relevant cardiovascular and metabolic alterations, leading to worsen clinical outcomes. In eligible patients, adrenalectomy is valid and safe option to treat SH, reducing cardiometabolic abnormalities.
Authors: Luigi Petramala; Giuseppe Cavallaro; Matteo Galassi; Cristiano Marinelli; Gianfranco Tonnarini; Antonio Concistrè; Umberto Costi; Maurizio Bufi; Piernatale Lucia; Giuseppe De Vincentis; Gino Iannucci; Giorgio De Toma; Claudio Letizia Journal: High Blood Press Cardiovasc Prev Date: 2017-01-31
Authors: S Bovio; A Cataldi; G Reimondo; P Sperone; S Novello; A Berruti; P Borasio; C Fava; L Dogliotti; G V Scagliotti; A Angeli; M Terzolo Journal: J Endocrinol Invest Date: 2006-04 Impact factor: 4.256
Authors: F Mantero; M Terzolo; G Arnaldi; G Osella; A M Masini; A Alì; M Giovagnetti; G Opocher; A Angeli Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Roberta Armignacco; Anne Jouinot; Lucas Bouys; Amandine Septier; Thomas Lartigue; Mario Neou; Cassandra Gaspar; Karine Perlemoine; Leah Braun; Anna Riester; Fidéline Bonnet-Serrano; Anne Blanchard; Laurence Amar; Carla Scaroni; Filippo Ceccato; Gian Paolo Rossi; Tracy Ann Williams; Casper K Larsen; Stéphanie Allassonnière; Maria-Christina Zennaro; Felix Beuschlein; Martin Reincke; Jérôme Bertherat; Guillaume Assié Journal: Eur J Endocrinol Date: 2022-01-13 Impact factor: 6.664
Authors: Jordan A Higgs; Alyssa P Quinn; Kevin D Seely; Zeke Richards; Shad P Mortensen; Cody S Crandall; Amanda E Brooks Journal: Int J Mol Sci Date: 2022-04-14 Impact factor: 6.208
Authors: Catherine D Zhang; Dingfeng Li; Ravinder Jeet Kaur; Andreas Ebbehoj; Sumitabh Singh; Elizabeth J Atkinson; Sara J Achenbach; William F Young; Wiebke Arlt; Walter A Rocca; Irina Bancos Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 6.134